지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2021.6
- 수록면
- 31 - 36 (6page)
이용수
초록· 키워드
오류제보하기
Purpose: Adjuvant chemotherapy (AC) improves survival outcomes in patients with advanced gastric cancer (GC) after curative surgery; however, some patients do not receive or complete chemotherapy. This study aimed to identify factors related to patient compliance with chemotherapy after curative surgery for advanced GC.
Methods: The data of patients who underwent curative gastrectomy for pathologic stage II–III GC between 2012 and 2016 were reviewed. Patients were divided into an AC completion group (group C), AC incompletion group (group I), and surgery-only group (group S). The AC regimen was either tegafur/gimeracil/oteracil (S-1) or capecitabine plus oxaliplatin (XELOX).
Results: The study enrolled 417 patients; group C had 222 patients, group I had 110, and group S had 85. The most common reason for not initiating AC was poor general condition (36.5%), while chemotherapy-related complications was the common reason for AC incompletion (43.6%). In multivariate analysis, age over 65 years, Eastern Cooperative Oncology Group performance status ≥1, Charlson comorbidity index ≥1, and the presence of postoperative complications were independent risk factors for not initiating AC (odds ratio: 4.32, 2.62, 1.84, and 2.17, respectively). Age over 65 years, longer postoperative stay, and XELOX regimen were significant risk factors for incompletion of AC (odds ratio: 2.68, 1.72, and 2.23, respectively).
Conclusion: Old age, poor performance status, comorbidities, and postoperative complications, longer postoperative hospital stay, and XELOX regimen were associated with poor compliance with AC in GC patients. Clinicians can improve compliance with AC by managing postoperative complications and selecting the most appropriate treatment regimen.
Methods: The data of patients who underwent curative gastrectomy for pathologic stage II–III GC between 2012 and 2016 were reviewed. Patients were divided into an AC completion group (group C), AC incompletion group (group I), and surgery-only group (group S). The AC regimen was either tegafur/gimeracil/oteracil (S-1) or capecitabine plus oxaliplatin (XELOX).
Results: The study enrolled 417 patients; group C had 222 patients, group I had 110, and group S had 85. The most common reason for not initiating AC was poor general condition (36.5%), while chemotherapy-related complications was the common reason for AC incompletion (43.6%). In multivariate analysis, age over 65 years, Eastern Cooperative Oncology Group performance status ≥1, Charlson comorbidity index ≥1, and the presence of postoperative complications were independent risk factors for not initiating AC (odds ratio: 4.32, 2.62, 1.84, and 2.17, respectively). Age over 65 years, longer postoperative stay, and XELOX regimen were significant risk factors for incompletion of AC (odds ratio: 2.68, 1.72, and 2.23, respectively).
Conclusion: Old age, poor performance status, comorbidities, and postoperative complications, longer postoperative hospital stay, and XELOX regimen were associated with poor compliance with AC in GC patients. Clinicians can improve compliance with AC by managing postoperative complications and selecting the most appropriate treatment regimen.
목차
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
참고문헌 (11)
참고문헌 신청
Guideline Committee of the Korean Gastric Cancer Association / 2019 / Korean Practice Guideline for Gastric Cancer 2018; Evidence-based, Multi-disciplinary Approach / Journal of Gastric Cancer 19(1):1~48
이창민 / 2020 / Long-term Efficacy of S-1 Monotherapy or Capecitabine Plus Oxaliplatin as Adjuvant Chemotherapy for Patients with Stage II or III Gastric Cancer after Curative Gastrectomy: a Propensity Score-Matched Multicenter Cohort Study / Journal of Gastric Cancer 20(2):152~164
Dong-Wook Kim / 2019 / Actual compliance to adjuvant chemotherapy in gastric cancer / Annals of Surgical Treatment and Research 96(4):185~190
장성호 / 2018 / The Prognostic Significance of Compliance with Postoperative Adjuvant Chemotherapy in Patients with Stage III Gastric Cancer: an Observational Study / Journal of Gastric Cancer 18(1):48~57
Yamashita K / 2017 / Risk factors for poor compliance with adjuvant S-1chemotherapy for gastric cancer : a multicenter retrospective study / Ann Surg Oncol 24:2639~2645
이창민 / 2020 / Long-term Efficacy of S-1 Monotherapy or Capecitabine Plus Oxaliplatin as Adjuvant Chemotherapy for Patients with Stage II or III Gastric Cancer after Curative Gastrectomy: a Propensity Score-Matched Multicenter Cohort Study / Journal of Gastric Cancer 20(2):152~164
Dong-Wook Kim / 2019 / Actual compliance to adjuvant chemotherapy in gastric cancer / Annals of Surgical Treatment and Research 96(4):185~190
장성호 / 2018 / The Prognostic Significance of Compliance with Postoperative Adjuvant Chemotherapy in Patients with Stage III Gastric Cancer: an Observational Study / Journal of Gastric Cancer 18(1):48~57
Yamashita K / 2017 / Risk factors for poor compliance with adjuvant S-1chemotherapy for gastric cancer : a multicenter retrospective study / Ann Surg Oncol 24:2639~2645
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
XELOX chemotherapy compliance after gastrectomy in elderly gastric cancer patients
대한외과학회 학술대회 초록집
2017 .11
-
Is Laparoscopic Common Bile Duct Exploration Safe for the Oldest Old Patients?
Annals of geriatric medicine and research
2022 .06
-
The Prognostic Significance of Compliance with Postoperative Adjuvant Chemotherapy in Patients with Stage III Gastric Cancer: an Observational Study
Journal of Gastric Cancer
2018 .03
-
Nutritional Status Indicators Affecting the Tolerability of Postoperative Chemotherapy After Total Gastrectomy in Patients With Gastric Cancer
Journal of Gastric Cancer
2022 .03
-
Use of a Comprehensive Geriatric Assessment to Predict Short-Term Postoperative Outcome in Elderly Patients With Colorectal Cancer
Annals of Coloproctology
2016 .01
-
Impact of Various Types of Comorbidities on the Outcomes of Laparoscopic Total Gastrectomy in Patients with Gastric Carcinoma
Journal of Gastric Cancer
2018 .09
-
Effects of Postoperative Complications and Surgical Approaches on the Timing of Chemotherapy Administration in Patients with Stage 2 and 3 Gastric Cancer
대한임상종양학회 학술대회지
2015 .02
-
Low Serum Albumin Level, Male Sex, and Total Gastrectomy Are Risk Factors of Severe Postoperative Complications in Elderly Gastric Cancer Patients
Journal of Gastric Cancer
2016 .03
-
Nutrition and chemotherapy compliance in gastric cancer patients
대한외과학회 학술대회 초록집
2016 .11
-
Prognostic impact of postoperative complication after gastrectomy for patient with gastric cancer in real world data
대한외과학회 학술대회 초록집
2019 .10
-
A Proposal for a New Prognostic Index to Predict Postoperative Complications in Gastric Cancer Patients
대한외과학회 학술대회 초록집
2023 .05
-
위 절제술에서 영양 상태와 수혈이 합병증에 미치는 영향
KOREAN JOURNAL OF CLINICAL ONCOLOGY
2016 .12
-
Does operation order has impacts on postoperative complications in gastric cancer patients? : A study of surgeon fatigue
KOREAN JOURNAL OF CLINICAL ONCOLOGY
2016 .12
-
Comparison between S-1 and XELOX as Adjuvant Chemotherapy for Advanced Gastric Cancer after D2 Lymph Node Dissection
대한외과학회 학술대회 초록집
2022 .05
-
Effect of Early Adjuvant Chemotherapy on Survival of Advanced Gastric Cancer Patients: a Propensity Score-matched Analysis
Journal of Gastric Cancer
2018 .03
-
Evaluation of the Survival Benefit of Different Chemotherapy Regimens in Patients with T1-2N0 Triple-Negative Breast Cancer
Journal of Breast Cancer
2015 .01
-
Effect of Age on Laparoscopic Surgery and Postoperative Chemotherapy in Elderly Patients With Colorectal Cancer
Annals of Coloproctology
2020 .01
-
Effect of Adjuvant Chemotherapy on Elderly Stage II High-Risk Colorectal Cancer Patients
Annals of Coloproctology
2021 .10
-
Surgical Effect on Postoperative Weight Change in Patients with Gastrectomy for early gastric cancer
대한외과학회 학술대회 초록집
2017 .11
-
Clinical Efficacy and Safety of Early Adjuvant Chemotherapy for Stage III Colon Cancer: Short-Term Outcomes of a Multicenter, Randomized, Open-Label, Phase 3 Trial
대한임상종양학회 학술대회지
2021 .06
이 논문의 저자 정보
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2021-514-001918837